SRUK has a 30 year legacy of supporting vital research into Scleroderma and Raynaud's phenomena. Existing originally as the two founding charities, the Raynaud's and Scleroderma Association (RSA) and the Scleroderma Society, and eventually coming together to achieve more. We have made it our mission to transform outcomes for patients, injecting much needed funding into highly promising research areas.
We've come a long way since 1985, when a diagnosis of scleroderma meant that you had a 60% chance of surviving more than 5 years. Now, in 2018, a diagnosis of scleroderma does not have to be so scary. The survival rate has gone up to 85%, and even more amazingly survival post renal failure has dramatically increased from 25% to 80%.
We also now have 6 specialist centres in England, some of which are providing support to other clinics to ensure that more people are receiving the appropriate treatment and care.
As part of our commitment to ensuring that our community is at the forefront of understanding the research that is carried out by our clinician researchers, we are publishing the'Inaugural Research Impact' Report. This report highlights how research has enabled the amazing progress that has been achieved over the last 30 years.
We've focused on four key areas:
- Understanding the cause of Scleroderma and Raynaud's
- Enabling better diagnosis for Scleroderma
- Earlier detection of Scleroderma and Raynaud's
- Developing the best treatments available
As a special sneak peek for our community members, here are some highlights from the report.
Understanding the cause of Scleroderma and Raynaud's
A genome wide association study to get to the root of the problem
Professor Chris Denton, Royal Free Hospital/University College London
A team of world class scleroderma scientists at the Royal Free hospital made a breakthrough, uncovering a potential mechanism behind pulmonary hypertension, one of the biggest risk factors in scleroderma. They have spotted how certain genes may be behind blood vessel changes, potentially spotting those patients most at risk of this deadly complication.
Every single thing that a cell can do, from colouring your eyes through to conducting thoughts across your brain, depends on a detailed and complex instruction manual called the genome. There are thousands of different instructions (or genes) that make us who we are. Yet cells don't follow all the genes all the time. A nerve cell and a skin cell behave very differently, and this is because they subscribe to different parts of this instruction manual.
The symptoms of a disease occur because cells start to follow instructions that they normally ignore. Sometimes this is because the cells themselves are faulty, other times it is because something, perhaps a bacteria or virus, is stressing the cell, changing its behaviour. In scleroderma, something causes the immune system to begin attacking the body, and these attacks cause damage to the cells, which defend themselves by changing the genes they use. In areas of extreme damage where repair is impossible, the cells form scar tissue.
If we can understand which genes are in play for Scleroderma or Raynaud's, we can begin to anticipate how each person's disease will behave, and begin to explore ways to intervene or even correct the problem.
This is not a simple challenge, yet it is one to which Professor Chris Denton has devoted almost 25 years of research, becoming a world authority in the process. His work is improving the ability of doctors to predict how scleroderma may behave, identifying which patients will respond best to certain treatments and even helping to develop new treatments.
Using cutting-edge techniques to study the genes involved in different forms of scleroderma, Chris' team uncovered a cluster of active genes that normally help control blood vessels and may be linked to many symptoms of scleroderma, including pulmonary hypertension, a major risk-factor in diffuse systemic scleroderma.
They discovered that the highly specialised cells that normally line our blood vessels start to follow incorrect genetic instructions, transforming them into a different type of cell without some of their specialised properties. The consequence is that the barriers to the blood vessels become very leaky, contributing to pulmonary hypertension, possibly by allowing a type of white blood cell that helps form scar tissue to interact with the vital tissue.
These major advances in understanding the mechanisms and genes behind some of the most serious scleroderma symptoms has opened up many opportunities for trialing new treatments, opportunities that Chris' team are set up to build upon.
Enabling better diagnosis for Scleroderma
Staging Interstitial Lung Disease: A world class system for clinical diagnosis
Dame Carol Black, Professor Athol Wells, Professor Chris Denton, Royal Free/Royal Brompton
A team of world-leading clinicians and scientists developed a life-saving algorithm that allows clinicians to rapidly diagnose lung fibrosis as well as an expert. Led by Dame Carol Black and Professor Chris Denton from the Royal Free Hospital and Professor Athol Wells from the Royal Brompton, this dream-team's solution is one of the most important advances in scleroderma diagnosis in recent years.
In recent times fibrosis of the lungs has become the number one cause of death in people with systemic scleroderma. For people with the most severe lung disease it is important to treat aggressively, squashing the immune response. But these treatments are harsh and can have severe side-effects. It is therefore vital for doctors to know which patients have the most advanced lung fibrosis so they can treat appropriately.
Unfortunately the standard way of assessing lung function just wasn't good enough. There is too much variability, and the complexity of achieving an accurate understanding is beyond all but the most experienced doctors.
Dame Carol Black and her colleagues' approach was to combine High Resolution Computed Tomography, a technique that takes accurate cross-sectional x-rays of the body and reconstructs an internal view of the lungs, with standard tests of the lung's performance. The revolutionary element was to create an algorithm that can draw on this information and classify a patient's degree of lung disease severity. They developed this test by working with over 200 people with scleroderma, and then evaluated their final model. Incredibly, in the trials, doctors with less than 2 years' experience were able to classify the severity of disease in a way comparable to highly experienced radiologists after only 10 minutes training. This technique has put the ability to assess a potentially fatal aspect of scleroderma into the hands of doctors everywhere and has gone on to become the international standard for assessment, quite literally revolutionizing a vital part of scleroderma medicine.